加拿大安大略省HIV感染者与非感染者COVID-19疫苗接种率:基于人群的回顾性队列研究
该研究使用加拿大安大略省2020年12月14日至2022年8月31日的人群数据,将社区居住的≥19岁HIV感染者与非HIV感染者按年龄、性别、地理和移民身份1:1匹配,采用修正Poisson回归和条件Poisson回归分析COVID-19疫苗接种率及预测因素。结果显示,20,903名HIV感染者中85.4%接种≥2剂,64.7%接种第三剂,24.3%接种第四剂;≥3剂接种存在性别差异(男性68.5% vs 女性50.9%),且HIV感染男性较非感染男性更可能接种≥3剂,而HIV感染女性较非感染女性更不可能接种≥3剂。
要点
- HIV感染者中85.4%接种≥2剂COVID-19疫苗,64.7%接种第三剂,24.3%接种第四剂。
- ≥3剂接种率存在性别差异:男性68.5% vs 女性50.9%。
- HIV感染男性较非感染男性更可能接种≥3剂,HIV感染女性较非感染女性更不可能接种≥3剂。
核心结论
- 加拿大安大略省HIV感染者前两剂COVID-19疫苗接种率较高,但≥3剂接种率仍存在差异,尤其是性别差异。
- 持续监测COVID-19疫苗接种率对于为加拿大HIV感染者制定免疫规划、政策和指南至关重要。
研究设计与样本
- 回顾性基于人群的匹配队列研究,使用省级临床和健康行政数据,时间范围为2020年12月14日至2022年8月31日。
- 社区居住的≥19岁HIV感染者按年龄、性别、地理和移民身份与非HIV诊断者1:1匹配。
- 采用修正Poisson回归(稳健标准误,考虑地理聚集)识别接种预测因素,采用条件Poisson回归(稳健误差方差)估计粗率和调整风险比及95%置信区间。
主要发现
- 20,903名HIV感染者中,85.4%接种≥2剂COVID-19疫苗,64.7%接种第三剂,24.3%接种第四剂。
- ≥3剂接种率存在性别差异:男性68.5% vs 女性50.9%。
- HIV感染者中接种≥3剂的预测因素包括年龄较大、男性性别和近期接种流感疫苗。
- HIV感染男性较非感染男性更可能接种≥3剂,而HIV感染女性较非感染女性更不可能接种≥3剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: COVID-19 vaccination significantly reduces COVID-19-related hospitalization and mortality and is important for those who may be at increased risk of SARS-CoV-2 infection, including people living with HIV. Using a population-based approach, we examined COVID-19 vaccine uptake among people living with and without HIV in Ontario, Canada. METHODS: A retrospective population-based matched cohort study was conducted using provincial clinical and health administrative data from December 14, 2020 to August 31, 2022. Community-dwelling adults living with HIV aged ≥19 years were matched one-to-one with a person without a diagnosis of HIV based on age, sex, geography, and immigration status. To identify predictors of vaccine uptake, modified Poisson regression with robust standard errors accounting for geographical clustering was used. To estimate vaccine uptake comparing the HIV and non-HIV cohorts, conditional Poisson regression with robust error variance was used to estimate crude and adjusted risk ratios with 95 % confidence intervals (CI). RESULTS: Among 20,903 people living with HIV, most (85.4%) had received ≥2 COVID-19 vaccine doses, with 64.7% receiving a third dose and 24.3% receiving a fourth dose. Disparities in uptake of ≥3 doses by sex were observed (males vs females: 68.5% vs 50.9%). Predictors of receiving ≥3 doses among people living with HIV included older age, male sex, and receipt of a recent influenza vaccine. Men living with HIV were more likely to receive ≥3 doses compared with men living without HIV, whereas women living with HIV were less likely than women living without HIV to receive ≥3 doses. CONCLUSIONS: Uptake of the first two doses of COVID-19 vaccine was high among people living with HIV in Ontario, Canada, however, disparities in uptake of ≥3 doses remain, especially by sex. Continued monitoring of COVID-19 vaccine uptake is crucial to informing immunization programs, policies and guidelines for people living with HIV in Canada.
引用
- Freitas C, Cooper CL, Kroch AE, et al. COVID-19 vaccine uptake in a retrospective population-based cohort of people living with and without HIV in Ontario, Canada. Vaccine. 2025. PMID: 40602344. doi:10.1016/j.vaccine.2025.127422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。